title: Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.
abstract: The ultimate goal of diagnostic research is a blood test detecting the risk of Alzheimer disease (AD) before neuronal damage develops. Current amyloid-beta (Abeta) tests do not detect the process leading to neurodegeneration. Novel immunologic and proteomics tests are based on aberrant appearance of inflammatory cytokines in the CSF and other protein biomarkers in the CSF or blood, and immune biomarkers of peripheral blood mononuclear cells (PBMC's). Cytokines, chemokines, complement factors, serum amyloid P component, and signaling proteins in the CSF or blood may be a rich source of diagnostic biomarkers, but the power of these tests will need to be examined in prospective studies. Recently-described flow cytometric test of defective Abeta phagocytosis detects patients with AD with a high sensitivity and specificity in distinct populations (confirmed AD patients vs. active University professors), but further experience is necessary for its use in general population at risk of AD. The analysis of the transcriptome of peripheral blood mononuclear cells "stressed" by Abeta is beginning to unravel the relations between specific pathways and AD. Thus novel diagnostic tests may provide biomarkers for pre-clinical detection, clarification of progression from MCI to AD, and follow-up of patients in clinical trials of immunostimulating therapies.
authors.affiliation: Departments of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA. fiala@mednet.ucla.edu
authors.forename: Milan
authors.initials: M
authors.lastname: Fiala
authors.forename: Robert
authors.initials: R
authors.lastname: Veerhuis
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000378:metabolism*; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D017628:Microglia / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis / Q000276:immunology*; D012307:Risk Factors
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers
references.citation: Neurology. 2005 May 10;64(9):1563-72
references.pmid: 15883317
references.citation: J Neurosci. 2008 Jul 2;28(27):6926-37
references.pmid: 18596167
references.citation: Glia. 2009 Jul;57(9):978-88
references.pmid: 19062178
references.citation: Neurol Sci. 2006 Apr;27(1):33-9
references.pmid: 16688597
references.citation: JAMA. 2003 Apr 23-30;289(16):2094-103
references.pmid: 12709467
references.citation: Neurobiol Aging. 1996 Sep-Oct;17(5):673-80
references.pmid: 8892339
references.citation: Acta Neuropathol. 2009 Feb;117(2):111-24
references.pmid: 19139910
references.citation: Neurobiol Aging. 2009 Nov;30(11):1885-9
references.pmid: 18378357
references.citation: Subcell Biochem. 2005;38:129-45
references.pmid: 15709476
references.citation: Brain. 2006 Nov;129(Pt 11):3042-50
references.pmid: 17071923
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12849-54
references.pmid: 17652175
references.citation: Lancet Neurol. 2003 Oct;2(10):605-13
references.pmid: 14505582
references.citation: Arch Neurol. 2007 Mar;64(3):366-70
references.pmid: 17353378
references.citation: Nat Med. 2007 Nov;13(11):1359-62
references.pmid: 17934472
references.citation: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references.pmid: 10858586
references.citation: J Alzheimers Dis. 2009;17(3):703-17
references.pmid: 19433889
references.citation: Ann Neurol. 2000 Apr;47(4):430-9
references.pmid: 10762153
references.citation: Int J Dev Neurosci. 2006 Apr-May;24(2-3):157-65
references.pmid: 16384684
references.citation: J Alzheimers Dis. 2006 Aug;9(3):293-348
references.pmid: 16914840
references.citation: J Neuroinflammation. 2006 Sep 27;3:27
references.pmid: 17005052
references.citation: J Neuroinflammation. 2005 Nov 21;2:27
references.pmid: 16300681
references.citation: J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5
references.pmid: 12933918
references.citation: Neurobiol Dis. 2009 Aug;35(2):128-40
references.pmid: 19010417
references.citation: J Neurosci. 2005 Nov 23;25(47):10884-93
references.pmid: 16306401
references.citation: J Neurosci. 2009 Mar 18;29(11):3603-12
references.pmid: 19295164
references.citation: Dement Geriatr Cogn Disord. 2008;26(6):522-7
references.pmid: 19052452
references.citation: Neurobiol Aging. 2008 May;29(5):669-75
references.pmid: 17208336
references.citation: Neurobiol Aging. 2005 Mar;26(3):341-7
references.pmid: 15639312
references.citation: Immunobiology. 2000 May;202(1):26-33
references.pmid: 10879686
references.citation: Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):235-48
references.pmid: 15975027
references.citation: Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23
references.pmid: 19372378
references.citation: Acta Neurol Scand. 2008 Jul;118(1):1-11
references.pmid: 18279484
references.citation: Ann Neurol. 2009 Feb;65(2):176-83
references.pmid: 19260027
references.citation: Neurosci Lett. 2007 Apr 6;416(1):87-91
references.pmid: 17317005
references.citation: J Neuroimmunol. 2009 May 29;210(1-2):67-72
references.pmid: 19329192
references.citation: Am J Pathol. 2007 Dec;171(6):1989-99
references.pmid: 18055545
references.citation: J Neurosci Res. 2002 Nov 1;70(3):462-73
references.pmid: 12391607
references.citation: Eur J Clin Invest. 2002 May;32(5):360-71
references.pmid: 12027877
references.citation: CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30
references.pmid: 19275634
references.citation: Arch Neurol. 2007 Mar;64(3):343-9
references.pmid: 17210801
references.citation: J Alzheimers Dis. 2005 Jun;7(3):221-32; discussion 255-62
references.pmid: 16006665
references.citation: J Neurol. 2007 Dec;254(12):1666-75
references.pmid: 17994313